<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030168</url>
  </required_header>
  <id_info>
    <org_study_id>IRB NO.779/62</org_study_id>
    <nct_id>NCT05030168</nct_id>
  </id_info>
  <brief_title>Effects of Low Protein Diet Supplemented With Ketoanalogues on Preservation of Kidney Function in Incremental Dialysis</brief_title>
  <official_title>The Effects of Low Protein Diet Supplemented With Ketoanalogues on Preservation of Residual Kidney Function Among Patients Undergoing Incremental Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that combination of incremental hemodialysis and ketoanologues&#xD;
      will better preserve residual kidney function and maintenance of nutritional status among the&#xD;
      incident ESRD patients during the early initiation of chronic dialysis. This hypothesis has&#xD;
      been a new concept of chronic hemodialysis initiation for End stage renal disease (ESRD)&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to conduct the first randomized Phase IIA clinical trial to&#xD;
      investigate the efficacy of incremental hemodialysis and moderately low protein diet combined&#xD;
      with ketoanologues supplementation on preservation of residual kidney function, inflammatory&#xD;
      status and nutritional parameters among incident chronic dialysis patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>residual renal function</measure>
    <time_frame>12 months</time_frame>
    <description>To demonstrate superiority effect of incremental hemodialysis (HD) protocol (initiate with once-weekly hemodialysis) plus ketoanalogues-supplemented low-protein diet during non-dialysis days over the standard HD protocol (initiate with twice weekly hemodialysis) on preservation of residual renal function (renal urea clearance) at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visceral protein</measure>
    <time_frame>12 months</time_frame>
    <description>To compare serum albumin levels between the two treatment groups over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural protein</measure>
    <time_frame>12 months</time_frame>
    <description>To compare muscle mass between the two treatment groups over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle function</measure>
    <time_frame>12 months</time_frame>
    <description>To compare muscle strength between the two treatment groups over 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Kidney Function</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Twice weekly hemodialysis program plus regular protein diet (1.0 g/kg/day) every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketosteril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Incremental hemodialysis program, starting from once weekly hemodialysis/hemodialysis filtration(HDF) plus low protein diet (0.6 g/kg/day) and ketoanologues 0.12g/kg/day supplementation on non-dialysis days and regular protein diet (1.0-1.2 g/kg/day) on dialysis day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketosteril</intervention_name>
    <description>ketoanalogues of essential amino acid</description>
    <arm_group_label>Ketosteril</arm_group_label>
    <other_name>incremental hemodialysis</other_name>
    <other_name>low protein diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years at screening&#xD;
&#xD;
          -  Stable CKD stage 5 not yet on dialysis with residual kidney function 5-10&#xD;
             ml/min/1.73m2 by CKD-EPI equation&#xD;
&#xD;
          -  Urine output ≥ 800 ml/day&#xD;
&#xD;
          -  Willing to participate in the study and can provide inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rapid glomerular filtration rate (GFR) progression defined as a decline of eGFR &gt;10&#xD;
             ml/min/1.73m2 by CKD-EPI equation in the prior 6 months before enrollment&#xD;
&#xD;
          -  Presence of wasting diseases, cancer cachexia, tuberculosis, AIDS wasting syndrome&#xD;
&#xD;
          -  Other active infection/inflammation determined by CRP &gt;10 mg/L&#xD;
&#xD;
          -  Severe gastrointestinal problem: persistent nausea/vomiting, dysphagia, chronic&#xD;
             diarrhea, severe malabsorption&#xD;
&#xD;
          -  Conditions at baseline requiring withdrawal from the study including severe protein&#xD;
             energy wasting by SGA and MIS score, prior kidney transplantation with&#xD;
             immunosuppressive agents or other serious medical conditions.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Uncontrolled hypercalcemia (persistent serum Ca ≥10.5 mg/dl)&#xD;
&#xD;
          -  BMI ≥ 35 kg/m2&#xD;
&#xD;
          -  Hypersensitivity to the active substances or to any of the excipients of Ketosteril&#xD;
&#xD;
          -  Disturbed amino acid metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Kearkiat Praditpornsilpa</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

